Shveta S Motwani1,2,3, Toni K Choueiri2,3, Ann H Partridge2,3, Jiani Hu2, Marina D Kaymakcalan2, Sushrut S Waikar1,3,4, Gary C Curhan1,3,5. 1. Renal Division, Brigham and Women's Hospital, Boston, Massachusetts. 2. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. 3. Harvard Medical School, Boston, Massachusetts. 4. Section of Nephrology, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts. 5. Channing Division of Network Medicine, Boston, Massachusetts.
Abstract
Background: Accurate estimation of kidney function is essential for patient selection and drug dosing in patients with cancer. eGFR equations are necessary for decision making and monitoring. Our aim was to identify which of these equations-estimated creatinine clearance (eCrCl) by Cockcroft-Gault (CG), eGFR by Modification of Diet in Renal Disease (eGFRMDRD), CKD Epidemiology Collaboration (eGFRCKD-EPI) or the recently proposed Janowitz-Williams equation (eGFRJ-W)-would be most suitable for GFR estimation among patients with cancer receiving cisplatin. Methods: We assembled a cohort of 5274 patients with cancer treated with cisplatin-based chemotherapy at two large cancer centers. We ascertained the frequency of cisplatin-associated AKI (C-AKI) defined as a ≥0.3 mg/dl rise in serum creatinine over baseline. We compared baseline eGFR and eCrCl using Bland-Altman (B-A) plots, coefficients of variation (CV), and concordance correlation coefficients. We calculated the positive predictive value (PPV), negative predictive value (PPV), accuracy, and area under the curve (AUC). Results: Patients were predominantly middle aged (median 58 years, IQR 49-66 years), overweight (median BMI 26.2, IQR 23.1-29.8 kg/m2), and White (88%), with a median baseline creatinine of 0.8 mg/dl and median cisplatin dose of 99 mg. C-AKI developed in 12% of the cohort. eGFRCKD-EPI had the highest PPV and AUC. eGFRCKD-EPI and eGFRMDRD, along with their BSA-modified counterparts, had the closest agreement with the lowest CV (7.2, 95% CI, 7.0 to 7.3) and the highest concordance. C-AKI was lowest when using eGFRCKD-EPI to define eGFR ≥60 ml/min per 1.73 m2. Conclusions: On the basis of its superior diagnostic performance, eGFRCKD-EPI should be used to estimate GFR in patients being considered for cisplatin-based chemotherapy.
Background: Accurate estimation of kidney function is essential for patient selection and drug dosing in patients with cancer. eGFR equations are necessary for decision making and monitoring. Our aim was to identify which of these equations-estimated creatinine clearance (eCrCl) by Cockcroft-Gault (CG), eGFR by Modification of Diet in Renal Disease (eGFRMDRD), CKD Epidemiology Collaboration (eGFRCKD-EPI) or the recently proposed Janowitz-Williams equation (eGFRJ-W)-would be most suitable for GFR estimation among patients with cancer receiving cisplatin. Methods: We assembled a cohort of 5274 patients with cancer treated with cisplatin-based chemotherapy at two large cancer centers. We ascertained the frequency of cisplatin-associated AKI (C-AKI) defined as a ≥0.3 mg/dl rise in serum creatinine over baseline. We compared baseline eGFR and eCrCl using Bland-Altman (B-A) plots, coefficients of variation (CV), and concordance correlation coefficients. We calculated the positive predictive value (PPV), negative predictive value (PPV), accuracy, and area under the curve (AUC). Results: Patients were predominantly middle aged (median 58 years, IQR 49-66 years), overweight (median BMI 26.2, IQR 23.1-29.8 kg/m2), and White (88%), with a median baseline creatinine of 0.8 mg/dl and median cisplatin dose of 99 mg. C-AKI developed in 12% of the cohort. eGFRCKD-EPI had the highest PPV and AUC. eGFRCKD-EPI and eGFRMDRD, along with their BSA-modified counterparts, had the closest agreement with the lowest CV (7.2, 95% CI, 7.0 to 7.3) and the highest concordance. C-AKI was lowest when using eGFRCKD-EPI to define eGFR ≥60 ml/min per 1.73 m2. Conclusions: On the basis of its superior diagnostic performance, eGFRCKD-EPI should be used to estimate GFR in patients being considered for cisplatin-based chemotherapy.
Authors: Silvia Titan; Shiyuan Miao; Hocine Tighiouart; Nan Chen; Hao Shi; Luxia Zhang; Zuo Li; Marc Froissart; Peter Rossing; Anders Grubb; Li Fan; Michael Mauer; Omran Bakoush; Christina Wyatt; Michael G Shlipak; Tariq Shafi; Lesley A Inker; Andrew S Levey Journal: Am J Kidney Dis Date: 2020-06-06 Impact factor: 8.860
Authors: Shveta S Motwani; Gearoid M McMahon; Benjamin D Humphreys; Ann H Partridge; Sushrut S Waikar; Gary C Curhan Journal: J Clin Oncol Date: 2018-01-10 Impact factor: 44.544
Authors: Andrew S Levey; Josef Coresh; Tom Greene; Lesley A Stevens; Yaping Lucy Zhang; Stephen Hendriksen; John W Kusek; Frederick Van Lente Journal: Ann Intern Med Date: 2006-08-15 Impact factor: 25.391
Authors: Lesley A Stevens; Christopher H Schmid; Tom Greene; Yaping Lucy Zhang; Gerald J Beck; Marc Froissart; Lee L Hamm; Julia B Lewis; Michael Mauer; Gerjan J Navis; Michael W Steffes; Paul W Eggers; Josef Coresh; Andrew S Levey Journal: Am J Kidney Dis Date: 2010-06-16 Impact factor: 8.860
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Sumanta K Pal; Nora Ruel; Sergio Villegas; Mark Chang; Kara DeWalt; Timothy G Wilson; Nicholas J Vogelzang; Bertram E Yuh Journal: PLoS One Date: 2014-04-10 Impact factor: 3.240